AI in Drug Discovery Market

Overview

The global AI in drug discovery market was valued at USD 2.8 billion in 2025 and is projected to reach USD 14.7 billion by 2032, expanding at a CAGR of 26.7% from 2026 to 2032. AI in drug discovery refers to the application of machine learning, deep learning, natural language processing, computer vision, and generative artificial intelligence technologies across the pharmaceutical research and development workflow, encompassing target identification and validation, virtual screening of chemical libraries, hit identification, lead optimization, preclinical candidate selection, and the prediction of pharmacokinetic, pharmacodynamic, and toxicological properties of drug candidates.

 

The ongoing geopolitical tensions and the 2025 U.S.–Iran conflict created short-term uncertainty across global pharmaceutical supply chains, cloud infrastructure operations, and cross-border AI semiconductor exports. However, the market impact remained moderately positive overall, as pharmaceutical companies accelerated AI-driven drug discovery investments to reduce development timelines and strengthen supply chain resilience Government research investment, regulatory modernization, and strategic national initiatives across major economies are functioning as critical structural enablers for AI in drug discovery commercialization. The U.S. National Institutes of Health (NIH) has directed over USD 1.7 billion since 2020 toward Bridge2AI, AIM-AHEAD, and Cancer AI initiatives that are building foundational biomedical AI infrastructure and training datasets. 

Market Size & Share

Market Dynamics

Generative AI Foundation Models for Molecular Design Are the Key Trend

The global AI in drug discovery market is being shaped most profoundly by the rapid maturation and commercial deployment of generative AI foundation models specifically architected for molecular and protein design, which are fundamentally redefining the speed and creativity achievable in early-stage drug discovery. U.S.–Iran conflict increased global focus on AI-enabled pharmaceutical innovation and accelerated adoption of generative AI platforms for faster drug discovery and healthcare preparedness. Geopolitical uncertainty also encouraged pharmaceutical companies to strengthen digital R&D infrastructure and reduce dependency on lengthy traditional discovery processes. Building on the breakthrough demonstrated by DeepMind's AlphaFold2 in solving the protein structure prediction problem at near-experimental accuracy across 200 million proteins, the industry has rapidly expanded into generative architectures including diffusion models for de novo molecule generation, transformer-based protein language models, and multimodal foundation models capable of simultaneously reasoning across chemical structures, protein targets, and biological pathway data. Isomorphic Labs, the Alphabet subsidiary spun out from DeepMind, signed combined upfront and milestone deals exceeding USD 2.9 billion with Eli Lilly and Novartis in 2024 to apply its AlphaFold-derived platform across multiple therapeutic programs.

 

Pharmaceutical R&D Productivity Crisis Is the Key Driver

The most powerful structural driver across the global AI in drug discovery market is the deepening pharmaceutical R&D productivity crisis, which has created an existential commercial imperative for the industry to adopt technologies capable of materially reducing drug development costs and improving clinical success rates. The average cost of bringing a new drug to market has risen above USD 2.6 billion according to Tufts Center for the Study of Drug Development estimates, while overall clinical trial success rates from Phase 1 to approval remain stuck at approximately 10 to 14% across therapeutic areas, with oncology success rates as low as 5%. The U.S.–Iran geopolitical tensions further intensified pressure on pharmaceutical companies to improve R&D productivity and accelerate therapeutic development timelines. This supported higher investment in AI-driven drug discovery platforms capable of reducing costs, improving clinical success rates, and strengthening supply chain resilience during global uncertainty. The combination of declining productivity per R&D dollar, accelerating patent cliffs threatening over USD 250 billion in branded pharmaceutical revenues by 2030, and intensifying competition from biosimilars and generics is compelling pharmaceutical executives to seek transformational improvements in discovery efficiency that incremental optimization of traditional methodologies cannot deliver.

 

Rare Disease and Personalized Medicine Applications Are the Key Opportunity

The most significant high-growth opportunity frontier for the global AI in drug discovery market is the application of AI-driven discovery platforms to rare disease and personalized medicine indications, where traditional pharmaceutical R&D economics have historically failed to support adequate investment despite substantial unmet medical need. The U.S. Orphan Drug Act, the EU Orphan Medicinal Product Regulation, and Japan's orphan drug designation framework collectively provide premium pricing, extended market exclusivity, and tax incentives that economically justify rare disease development, but the small patient populations and biological complexity of these conditions require dramatically more efficient discovery approaches than traditional methods can provide. The conflict created new opportunities for AI in drug discovery companies as governments and healthcare organizations increased focus on domestic drug development, rare disease preparedness, and faster response capabilities for future healthcare emergencies. Rising strategic investment in localized pharmaceutical innovation is expected to support long-term adoption of AI-driven discovery technologies. 

Global AI in Drug Discovery Market Size, 2025–2032 (USD Billion)

Segmentation Analysis

Analysis by Component

The software platforms segment held the largest market share of 65.0% in 2025, representing the dominant commercial category across the AI in drug discovery market and encompassing the full spectrum of AI-driven discovery platforms ranging from specialized point solutions for protein structure prediction, virtual screening, and molecular property prediction to integrated end-to-end discovery platforms spanning target identification through preclinical candidate selection.

 

The services segment will grow at the fastest CAGR of approximately 26.9% during the forecast period, propelled by the rapid expansion of AI-enabled discovery service providers offering project-based engagements with pharmaceutical and biotechnology customers seeking access to AI capabilities without long-term platform commitments. AI-driven contract research organizations including Recursion, Insilico Medicine, and emerging service-oriented players are growing service revenue rapidly through time-and-materials engagements, milestone-driven discovery programs, and outsourced specific workflows including target identification, hit-to-lead optimization, and ADMET prediction.

 

Component categories include:

•      Software Platforms (Largest Category)

•      Services (Fastest-Growing Category)

•      Hardware Infrastructure

 

Analysis by Technology

The machine learning segment held the largest market share of 45.0% in 2025, reflecting its foundational role across virtually all AI in drug discovery applications including molecular property prediction, ADMET forecasting, target identification, virtual screening, and lead optimization workflows. Machine learning encompasses the broadest class of supervised, unsupervised, and reinforcement learning algorithms applied to chemical structure data, protein sequences, biological pathway information, and clinical outcomes datasets, providing the foundational predictive infrastructure on which more specialized AI capabilities including generative AI and computer vision are built.

 

The generative AI segment will grow at the fastest CAGR of approximately 26.7% during the forecast period, driven by the rapid commercial deployment of diffusion models, transformer-based protein language models, and multimodal foundation models for de novo molecular and protein design applications.

 

Technology categories include:

•      Machine Learning (Largest Category)

•      Natural Language Processing (NLP)

•      Computer Vision

•      Generative AI (Fastest-Growing Category)

 

Analysis by Drug Modality

The small molecule drugs segment held the largest market share of 45.0% in 2025, reflecting the dominant share of small molecule chemistry in the global pharmaceutical R&D pipeline and the relative maturity of AI-driven design methodologies for small molecule applications. Small molecule drug discovery benefits from decades of accumulated chemical structure databases including ChEMBL, PubChem, and proprietary pharmaceutical company libraries, well-characterized predictive models for molecular properties including solubility, permeability, and metabolic stability, and an established medicinal chemistry framework that AI tools can augment rather than replace.

 

The RNA-based therapeutics segment will grow at the fastest CAGR of approximately 27.1% during the forecast period, driven by the explosive commercial success of mRNA vaccines establishing RNA modalities as a validated therapeutic class, the rapid expansion of small interfering RNA (siRNA) and antisense oligonucleotide (ASO) approvals, and the unique suitability of AI-driven design approaches for RNA structure prediction, target binding optimization, and delivery system design.

 

Drug modality categories include:

•      Small Molecule Drugs (Largest Category)

•      Biologics

•      Gene & Cell Therapies

•      RNA-Based Therapeutics (Fastest-Growing Category)

 

Analysis by Discovery Workflow

The hit identification segment held the largest market share of 45.0% in 2025, reflecting its position as the workflow stage where AI-driven approaches deliver the most quantifiable and immediately commercially valuable productivity improvements across the drug discovery process.

 

The target identification and validation segment will grow at the fastest CAGR of approximately 26.8% during the forecast period, propelled by the rapid maturation of AI platforms capable of integrating multimodal biological data including genomics, proteomics, transcriptomics, single-cell sequencing, and biological literature to identify novel disease-relevant targets that traditional approaches have failed to recognize.

 

Discovery workflow categories include:

•      Target Identification & Validation (Fastest-Growing Category)

•      Hit Identification (Largest Category)

•      Lead Optimization

•      Preclinical Candidate Selection

 

Analysis by Deployment Mode

The cloud-based segment held the largest market share of 60.0% in 2025, representing the dominant deployment mode for AI in drug discovery platforms and reflecting the structural alignment of cloud computing with the computational intensity, data scale, and collaboration requirements of modern AI-driven pharmaceutical research.

 

The hybrid segment will grow at the fastest CAGR of approximately 27.0% during the forecast period, driven by pharmaceutical industry preferences for combining cloud scalability for non-sensitive workloads with on-premise security for proprietary chemical structure data, sensitive patient information, and competitively critical R&D pipelines.

 

Deployment mode categories include:

•      Cloud-Based (Largest Category)

•      On-Premises

•      Hybrid (Fastest-Growing Category)

 

Analysis by Therapeutic Area

The oncology segment held the largest market share of 30.0% in 2025, reflecting the therapeutic area's position as the largest pharmaceutical R&D investment category globally and the concentration of AI-driven discovery activity targeting cancer indications. Oncology benefits from the broadest available training datasets including The Cancer Genome Atlas (TCGA), Project GENIE, the International Cancer Genome Consortium, and substantial proprietary pharmaceutical company datasets, providing the data foundation required for high-performance AI model training across cancer drug discovery applications.

 

The rare diseases segment will grow at the fastest CAGR of approximately 26.9% during the forecast period, propelled by the unique suitability of AI approaches for the small patient populations, biological complexity, and economic constraints that characterize rare disease drug development.

 

Therapeutic area categories include:

•      Oncology (Largest Category)

•      Neurological Disorders

•      Cardiovascular Diseases

•      Infectious Diseases

•      Metabolic Disorders

•      Immunological Disorders

•      Rare Diseases (Fastest-Growing Category)

 

Analysis by End User

The pharmaceutical companies segment held the largest market share of 45.0% in 2025, representing the dominant end-user category for AI in drug discovery platforms and services. The pharmaceutical industry's combined R&D expenditure exceeded USD 250 billion in 2024, with growing portions of discovery budgets directed toward AI-augmented programs and AI partnerships.

 

The biotechnology companies segment will grow at the fastest CAGR of approximately 27.3% during the forecast period, driven by the rapid emergence and scale-up of AI-native biotechs that combine novel AI capabilities with traditional drug development infrastructure, and the broader biotechnology industry's accelerating adoption of third-party AI platforms to augment internal discovery capabilities.

 

End user categories include:

•      Pharmaceutical Companies (Largest Category)

•      Biotechnology Companies (Fastest-Growing Category)

•      Contract Research Organizations (CROs)

•      Academic & Research Institutes

By Region

AI in Drug Discovery Market Regional Analysis

North America held the largest market share of 42.0% in 2025, driven by the concentration of leading AI in drug discovery companies, the world's most advanced pharmaceutical and biotechnology industry, exceptional NIH research funding for AI-enabled biomedical research, and the regulatory leadership represented by the FDA's progressive guidance frameworks for AI evidence in drug submissions. The ongoing U.S.–Iran conflict had a moderately positive impact on the North American AI in drug discovery market, as U.S. pharmaceutical and biotechnology companies increased focus on accelerating domestic drug development and healthcare innovation. Rising geopolitical uncertainty also encouraged higher investment in AI-based R&D platforms, cloud infrastructure, and faster therapeutic discovery capabilities. The U.S. market benefits from the world's highest concentration of AI talent across leading research universities and technology companies, the most commercially advanced biopharmaceutical industry with the greatest capacity to fund AI partnerships and adopt AI-driven discovery workflows, and the NIH's USD 1.7 billion-plus investment in AI-enabled biomedical research since 2020 through Bridge2AI, AIM-AHEAD, and complementary initiatives.

 

Asia-Pacific will grow at the fastest CAGR of approximately 27.5% during the forecast period, projected to expand at a CAGR exceeding 30% through 2032, driven by the rapid scale-up of AI in drug discovery activity across China, Japan, South Korea, India, and Singapore, supported by substantial government investment, expanding biopharmaceutical industry capacity, and the integration of regional AI talent pools into pharmaceutical research applications. The U.S.–Iran conflict created mixed impacts across the Asia-Pacific AI in drug discovery market. Countries such as China, India, Japan, and South Korea increased focus on strengthening domestic pharmaceutical research and AI-enabled healthcare innovation to reduce dependency on Western supply chains and imported technologies. China's New Generation AI Development Plan has explicitly identified AI-driven drug discovery as a national strategic priority, mobilizing substantial state investment in domestic AI biotechs including Insilico Medicine (which relocated headquarters to Hong Kong), XtalPi, Galixir, and Engine Biosciences, supported by accelerated regulatory pathways under the National Medical Products Administration (NMPA) for innovative pharmaceuticals.

 

Countries and region include:

• North America (Largest Regional Market)

o    U.S. (Larger and Faster-Growing Country Market)

o    Canada

• Europe

o      Germany (Largest Country Market)

o      U.K. (Fastest-Growing Country Market)

o      France

o      Italy

o      Spain

o      Rest of Europe

• Asia Pacific (Fastest-Growing Regional Market)

o      China (Largest Country Market)

o      India (Fastest-Growing Country Market)

o      Japan

o      South Korea

o      Australia

o      Rest of APAC

• Latin America

o     Brazil (Largest Country Market)

o     Mexico (Fastest-Growing Country Market)

o     Rest of LATAM

• Middle East and Africa

o      Saudi Arabia (Largest Country Market)

o      South Africa (Fastest-Growing Country Market)

o      U.A.E.

o      Rest of MEA

Market Share

The global AI in drug discovery market is highly fragmented in nature, because it consists of a large number of technology providers, biotechnology companies, pharmaceutical firms, cloud platform vendors, and AI startups competing across different stages of the drug development process. No single company currently dominates the entire market, as organizations specialize in different capabilities such as target identification, molecule screening, predictive modeling, clinical trial optimization, generative AI, protein structure prediction, and biomarker discovery. The market is evolving rapidly with continuous entry of new startups and niche AI companies that focus on specific therapeutic areas or proprietary algorithms. Many small and mid-sized firms possess specialized machine learning models, deep learning platforms, or biological datasets that give them competitive advantages in narrow application areas.

 

Key Players Covered

•      Recursion Pharmaceuticals, Inc. (U.S.)

•      Isomorphic Labs (U.K.)

•      Insilico Medicine (Hong Kong)

•      BenevolentAI plc (U.K.)

•      Generate Biomedicines, Inc. (U.S.)

•      Atomwise Inc. (U.S.)

•      Absci Corporation (U.S.)

•      BigHat Biosciences, Inc. (U.S.)

•      Owkin, Inc. (France)

•      Schrödinger, Inc. (U.S.)

•      Cyclica Inc. (Canada)

•      Deep Genomics Incorporated (Canada)

•      XtalPi Inc. (China)

•      Google DeepMind (U.S.)

 

Market News

• In December 2025, Generate Biomedicines, Inc. announced plans to initiate global Phase 3 studies for GB-0895, an AI-engineered long-acting anti-TSLP antibody for severe asthma. The program marked one of the most advanced late-stage clinical developments in the AI-enabled biologics discovery market, highlighting the growing role of generative AI in therapeutic protein design.
• In November 2024, Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc, creating one of the largest publicly traded AI-enabled drug discovery companies. The merger combined Recursion’s phenotypic screening and machine learning platform with Exscientia’s AI-driven molecular design capabilities, strengthening end-to-end drug discovery across target identification, medicinal chemistry, and preclinical development.
• In January 2024, Isomorphic Labs announced a strategic multi-target research collaboration with Eli Lilly and Company focused on AI-driven small-molecule drug discovery. Under the agreement, Isomorphic Labs became eligible to receive up to approximately USD 1.7 billion in milestone payments, excluding royalties.

Frequently Asked Questions